{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:41:57Z","timestamp":1787064117308,"version":"build-2736575974"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004603","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000}}],"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"US National Institutes of Health\/ National Institute of Allergy and Infectious Diseases","award":["R01AI146555"],"award-info":[{"award-number":["R01AI146555"]}]},{"name":"Social Sciences and Humanities Research Council of Canada Doctoral Fellowship","award":["752-2022-0285"],"award-info":[{"award-number":["752-2022-0285"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Host-response-based transcriptional signatures (HrTS) have been developed to identify \u201cincipient tuberculosis (TB)\u201d. No study has reported the cost-effectiveness of HrTS for post-arrival migrant screening programs in low-incidence countries. The aim of this study was to assess the potential health impact and cost-effectiveness of HrTS for post-arrival TB infection screening among new migrants in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We used a discrete-event simulation model to compare four strategies: (1) no screening for TB infection or incipient TB; (2) \u2018IGRA-only\u2019, screen all with interferon-gamma release assay (IGRA), provide TB preventive treatment for IGRA-positives; (3) \u2018IGRA-HrTS\u2019, screen all with IGRA followed by HrTS for IGRA-positives, provide incipient TB treatment for individuals testing positive with both tests; and (4) \u2018HrTS-only\u2019, screen all with HrTS, provide incipient TB treatment for HrTS-positives. We assessed outcomes over the lifetime of migrants entering the United Stataes (U.S.) in 2019, assuming HrTS met WHO Target Product Profile (TPP) optimal criteria. We conducted sensitivity analyses to evaluate the robustness of results. Our findings show that at a willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY) gained, the IGRA-only strategy was the optimal strategy under both healthcare sector and societal perspectives, with an incremental cost-effectiveness ratio (ICER) of $104,138 and $143,103 per QALY gained, respectively. At a willingness-to-pay of $100,000 per QALY gained the IGRA-HrTS strategy appeared optimal. When the cohort was stratified by TB incidence in the country-of-origin, the IGRA-only strategy was optimal for country-of-origin incidence\n                      <jats:inline-formula id=\"pmed.1004603.e001\">\n                        <jats:alternatives>\n                          <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" id=\"pmed.1004603.e001g\" mimetype=\"image\" position=\"anchor\" xlink:href=\"info:doi\/10.1371\/journal.pmed.1004603.e001\" xlink:type=\"simple\"\/>\n                          <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" display=\"inline\" id=\"equation1\">\n                            <mml:mrow>\n                              <mml:mo>\u2265<\/mml:mo>\n                            <\/mml:mrow>\n                          <\/mml:math>\n                        <\/jats:alternatives>\n                      <\/jats:inline-formula>\n                      100 per 100,000, and the no-screening strategy was optimal for country-of-origin incidence &lt;10 per 100,000. The IGRA-HrTS strategy was potentially cost-effective with country-of-origin incidence of 10\u2013100 per 100,000, though this result had substantial uncertainty. Results were sensitive to time trends in TB progression risk after U.S. entry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An HrTS test meeting WHO TPP optimal criteria would be potentially cost-effective for post-arrival screening among a subset of U.S. migrants, but this result was sensitive to multiple factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004603","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:45:53Z","timestamp":1746711953000},"page":"e1004603","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of screening with transcriptional signatures for incipient TB among U.S. migrants"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-534X","authenticated-orcid":true,"given":"Yuli Lily","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-7895","authenticated-orcid":true,"given":"C. Robert","family":"Horsburgh Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-7198","authenticated-orcid":true,"given":"Ted","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-1581","authenticated-orcid":true,"given":"Jeffrey W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3929-5515","authenticated-orcid":true,"given":"Joshua A.","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-016X","authenticated-orcid":true,"given":"Nicolas A.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"10","key":"pmed.1004603.ref001","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"RMGJ Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"3","key":"pmed.1004603.ref002","doi-asserted-by":"crossref","first-page":"1900655","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"A Cohen","year":"2019","journal-title":"Eur Respir J"},{"issue":"10","key":"pmed.1004603.ref003","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","article-title":"Prognostic value of feron-\u03b3 release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study","volume":"18","author":"I Abubakar","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pmed.1004603.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059652","article-title":"TB incidence in an adolescent cohort in South Africa","volume":"8","author":"H Mahomed","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"pmed.1004603.ref005","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1164\/rccm.201502-0232OC","article-title":"Risk assessment of tuberculosis in contacts by IFN-\u03b3 release assays. a tuberculosis network European trials Group Study","volume":"191","author":"J-P Zellweger","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"pmed.1004603.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169539","article-title":"Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-burden setting","volume":"12","author":"SK Sharma","year":"2017","journal-title":"PLoS One"},{"key":"pmed.1004603.ref007","unstructured":"World Health Organization. Development of a target product profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. 2017."},{"issue":"3","key":"pmed.1004603.ref008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1473-3099(20)30914-2","article-title":"Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial","volume":"21","author":"TJ Scriba","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"pmed.1004603.ref009","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00021-18","article-title":"Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection","volume":"31","author":"PK Drain","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"pmed.1004603.ref010","first-page":"8567893","article-title":"Immigrant arrival and tuberculosis among large immigrant- and refugee-receiving countries, 2005-2009","volume":"2017","author":"Z White","year":"2017","journal-title":"Tuberc Res Treat"},{"issue":"11","key":"pmed.1004603.ref011","doi-asserted-by":"crossref","first-page":"286","DOI":"10.15585\/mmwr.mm6911a3","article-title":"Tuberculosis\u2014United States, 2019","volume":"69","author":"NG Schwartz","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"pmed.1004603.ref012","article-title":"Recent transmission of tuberculosis\u2014United States, 2011-2014","volume":"11","author":"CM Yuen","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"pmed.1004603.ref013","doi-asserted-by":"crossref","first-page":"965","DOI":"10.5588\/ijtld.16.0935","article-title":"Effectiveness and cost-effectiveness of screening migrants for active tuberculosis and latent tuberculous infection","volume":"21","author":"D Zenner","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"pmed.1004603.ref014","doi-asserted-by":"crossref","first-page":"100419","DOI":"10.1016\/j.epidem.2020.100419","article-title":"High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000-2016","volume":"33","author":"AN Hill","year":"2020","journal-title":"Epidemics"},{"issue":"9","key":"pmed.1004603.ref015","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1513\/AnnalsATS.201604-302LE","article-title":"Proposed approach for 4-month treatment of culture-negative pulmonary tuberculosis in adults","volume":"13","author":"Y Hamada","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"pmed.1004603.ref016","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/thoraxjnl-2018-211715","article-title":"Evaluating latent tuberculosis infection diagnostics using latent class analysis","volume":"73","author":"JE Stout","year":"2018","journal-title":"Thorax"},{"issue":"4","key":"pmed.1004603.ref017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(19)30282-6","article-title":"Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis","volume":"8","author":"RK Gupta","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"9","key":"pmed.1004603.ref018","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1662","article-title":"Prevalence of latent tuberculosis infection among non-US-born persons by country of birth-United States, 2012-2017","volume":"73","author":"JM Collins","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pmed.1004603.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249012","article-title":"State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity","volume":"16","author":"A Mirzazadeh","year":"2021","journal-title":"PLoS One"},{"key":"pmed.1004603.ref020","volume-title":"Living longer: historical and projected life expectancy in the United States, 1960 to 2060","author":"L Medina","year":"2020"},{"issue":"4","key":"pmed.1004603.ref021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0021-9991(76)90041-3","article-title":"A general method for numerically simulating the stochastic time evolution of coupled chemical reactions","volume":"22","author":"DT Gillespie","year":"1976","journal-title":"J Comput Phy"},{"key":"pmed.1004603.ref022","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2021"},{"key":"pmed.1004603.ref023","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"PJ Neumann","year":"2016"},{"issue":"9","key":"pmed.1004603.ref024","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"PJ Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"pmed.1004603.ref025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force--6","volume":"15","author":"AH Briggs","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"pmed.1004603.ref026","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12916-021-02127-w","article-title":"The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study","volume":"19","author":"T Sumner","year":"2021","journal-title":"BMC Med"},{"key":"pmed.1004603.ref027","author":"A Halliday","year":"2021"},{"issue":"10","key":"pmed.1004603.ref028","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/ciz034","article-title":"Diagnostic accuracy of early secretory antigenic target-6-free interferon-gamma release assay compared to QuantiFERON-TB Gold In-tube","volume":"69","author":"E Nemes","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pmed.1004603.ref029","doi-asserted-by":"crossref","first-page":"45969","DOI":"10.1038\/srep45969","article-title":"Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6","volume":"7","author":"M Ruhwald","year":"2017","journal-title":"Sci Rep"},{"key":"pmed.1004603.ref030"},{"issue":"17","key":"pmed.1004603.ref031","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/jama.2023.3954","article-title":"Screening for latent tuberculosis infection in adults: updated evidence report and systematic review for the US preventive services task force","volume":"329","author":"DE Jonas","year":"2023","journal-title":"JAMA"},{"key":"pmed.1004603.ref032"},{"issue":"7","key":"pmed.1004603.ref033","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"AL Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pmed.1004603.ref034","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis","volume":"167","author":"D Zenner","year":"2017","journal-title":"Ann Intern Med"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004603","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T16:35:48Z","timestamp":1747845348000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004603"}},"subtitle":[],"editor":[{"given":"Claudia M.","family":"Denkinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004603","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.09.24315062","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}